|
1
|
Morton J: Pineapple. Fruits of Warm
Climates. Julia F. Morton. (Miami, FL). 18–28. 1987.
|
|
2
|
Scopes RK: Protein Purification:
Principles and Practice (2nd). Springer-Verlag. New York, NY:
41–65. 1982.
|
|
3
|
Arnon R and Shapira E: Antibodies to
papain. A selective fractionation according to inhibitory capacity.
Biochemistry. 6:3942–3950. 1967. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ota S, Moore S and Stein WH: Preparation
and chemical properties of purified stem and fruit bromelains.
Biochemistry. 3:180–185. 1964. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Murachi T, Yasui M and Yasuda Y:
Purification and physical characterization of stem bromelain.
Biochemistry. 3:48–55. 1964. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hale LP, Greer PK, Trinh CT and James CL:
Proteinase activity and stability of natural bromelain
preparations. Int Immunopharmacol. 5:783–793. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Devakate RV, Patil VV, Waje SS and Thorat
BN: Purification and drying of bromelain. Separ Purif Tech.
64:259–264. 2009. View Article : Google Scholar
|
|
8
|
Castell JV, Friedrich G, Kuhn CS and Poppe
GE: Intestinal absorption of undegraded proteins in men: presence
of bromelain in plasma after oral intake. Am J Physiol.
273:G139–G146. 1997.PubMed/NCBI
|
|
9
|
Maurer HR: Bromelain: Biochemistry,
pharmacology and medical use. Cell Mol Life Sci. 58:1234–1245.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Mialovyts'ka OA: Effect of phlogenzym in
long-term treatment of patients with multiple sclerosis. Lik
Sprava. 109–113. 2003.(In Ukrainian).
|
|
11
|
White RR, Crawley FE, Vellini M and Rovati
LA: Bioavailability of 125I bromelain after oral administration to
rats. Biopharm Drug Dispos. 9:397–403. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Taussig SJ and Batkin S: Bromelain, the
enzyme complex of pineapple (Ananas comosus) and its
clinical application. An update. J Ethnopharmacol. 22:191–203.
1988. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Brien S, Lewith G, Walker A, Hicks SM and
Middleton D: Bromelain as a treatment for osteoarthritis: a review
of clinical studies. Evid Based Complement Alternat Med. 1:251–257.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hale LP: Proteolytic activity and
immunogenicity of oral bromelain within the gastrointestinal tract
of mice. Int Immunopharmacol. 4:255–264. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sarkar FH and Li Y: Cell signaling
pathways altered by natural chemopreventive agents. Mutat Res.
555:53–64. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Huang JR, Wu CC, Hou RC and Jeng KC:
Bromelain inhibits lipopolysaccharide-induced cytokine production
in human THP-1 monocytes via the removal of CD14. Immunol Invest.
37:263–277. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Bhui K, Prasad S, George J and Shukla Y:
Bromelain inhibits COX-2 expression by blocking the activation of
MAPK regulated NF-kappa B against skin tumor-initiation triggering
mitochondrial death pathway. Cancer Lett. 282:167–176. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Gaspani L, Limiroli E, Ferrario P and
Bianchi M: In vivo and in vitro effects of bromelain on PGE(2) and
SP concentrations in the inflammatory exudate in rats.
Pharmacology. 65:83–86. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Desser L, Rehberger A and Paukovits W:
Proteolytic enzymes and amylase induce cytokine production in human
peripheral blood mononuclear cells in vitro. Cancer Biother.
9:253–263. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Engwerda CR, Andrew D, Murphy M and Mynott
TL: Bromelain activates murine macrophages and natural killer cells
in vitro. Cell Immunol. 210:5–10. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Engwerda CR, Andrew D, Ladhams A and
Mynott TL: Bromelain modulates T cell and B cell immune responses
in vitro and in vivo. Cell Immunol. 210:66–75. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Barth H, Guseo A and Klein R: In vitro
study on the immunological effect of bromelain and trypsin on
mononuclear cells from humans. Eur J Med Res. 10:325–331.
2005.PubMed/NCBI
|
|
23
|
Onken JE, Greer PK, Calingaert B and Hale
LP: Bromelain treatment decreases secretion of pro-inflammatory
cytokines and chemokines by colon biopsies in vitro. Clin Immunol.
126:345–352. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hale LP, Greer PK, Trinh CT and Gottfried
MR: Treatment with oral bromelain decreases colonic inflammation in
the IL-10-deficient murine model of inflammatory bowel disease.
Clin Immunol. 116:135–142. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Stopper H, Schinzel R, Sebekova K and
Heidland A: Genotoxicity of advanced glycation end products in
mammalian cells. Cancer Lett. 190:151–156. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Makrydimas G, Zagorianakou N, Zagorianakou
P and Agnantis NJ: CD44 family and gynaecological cancer. In Vivo.
17:633–640. 2003.PubMed/NCBI
|
|
27
|
Subramaniam V, Gardner H and Jothy S:
Soluble CD44 secretion contributes to the acquisition of aggressive
tumor phenotype in human colon cancer cells. Exp Mol Pathol.
83:341–346. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Massagué J: TGFbeta in Cancer. Cell.
134:215–230. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Bierie B and Moses HL: Tumour
microenvironment: TGFbeta: the molecular Jekyll and Hyde of cancer.
Nat Rev Cancer. 6:506–520. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
30
|
Leipner J, Iten F and Saller R: Therapy
with proteolytic enzymes in rheumatic disorders. BioDrugs.
15:779–789. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Vellini M, Desideri D, Milanese A, Omini
C, Daffonchio L, Hernandez A and Brunelli G: Possible involvement
of eicosanoids in the pharmacological action of bromelain.
Arzneimittelforschung. 36:110–112. 1986.PubMed/NCBI
|
|
32
|
Inoue K, Motonaga A, Dainaka J, Nishimura
T, Hashii H, Yamate K, Ueda F and Kimura K: Effect of etodolac on
prostaglandin E2 biosynthesis, active oxygen generation and
bradykinin formation. Prostaglandins Leukot Essent Fatty Acids.
51:457–462. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Oh-ishi S, Uchida Y, Ueno A and Katori M:
Bromelian, a thiolprotease from pineapple stem, depletes high
molecular weight kininogen by activation of Hageman factor (Factor
XIII). Thromb Res. 14:665–672. 1979. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Seligman B: Bromelain: An
anti-inflammatory agent. Angiology. 13:508–510. 1962. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Giacca S: Clinical experiences on the
action of bromelin in peripheral venous diseases and in chronic
bronchitic states. Minerva Med. 56:1041965.(In Italian).
|
|
36
|
Moss JN, Frazier CV and Martin GJ:
Bromelains. The pharmacology of the enzymes. Arch Int Pharmacodyn
Ther. 145:166–189. 1963.PubMed/NCBI
|
|
37
|
De-Giuli M and Pirotta F: Bromelain,
interaction with some protease inhibitor and rabbit specific
antiserum. Drugs Exp Clin Res. 4:21–23. 1978.
|
|
38
|
Chobotova K, Vernallis AB and Majid FA:
Bromelain's activity and potential as an anti-cancer agent: current
evidence and perspectives. Cancer Lett. 290:148–156. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Beuth J and Braun JM: Modulation of murine
tumor growth and colonization by bromelaine, an extract of the
pineapple plant (Ananas comosum L.). In Vivo. 19:483–485.
2005.PubMed/NCBI
|
|
40
|
Báez R, Lopes MT, Salas CE and Hernández
M: In vivo antitumoral activity of stem pineapple (Ananas
comosus) bromelain. Planta Med. 73:1377–1383. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Zavadova E, Desser L and Mohr T:
Stimulation of reactive oxygen species production and cytotoxicity
in human neutrophils in vitro and after oral administration of a
polyenzyme preparation. Cancer Biother. 10:147–152. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Eckert K, Grabowska E, Stange R, Schneider
U, Eschmann K and Maurer HR: Effects of oral bromelain
administration on the impaired immunocytotoxicity of mononuclear
cells from mammary tumor patients. Oncol Rep. 6:1191–1199.
1999.PubMed/NCBI
|
|
43
|
Snowden HM, Renfrew MJ and Woolridge MW:
Treatments for breast engorgement during lactation. Cochrane
Database Syst Rev. 2:CD0000462001.PubMed/NCBI
|
|
44
|
Guimarães-Ferreira CA, Rodrigues EG,
Mortara RA, Cabral H, Serrano FA, Ribeiro-dos-Santos R and
Travassos LR: Antitumor effects in vitro and in vivo and mechanisms
of protection against melanoma B16F10-Nex2 cells by fastuosain, a
cysteine proteinase from Bromelia fastuosa. Neoplasia.
9:723–733. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Tysnes BB, Maurer HR, Porwol T, Probst B,
Bjerkvig R and Hoover F: Bromelain reversibly inhibits invasive
properties of glioma cells. Neoplasia. 3:469–479. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Mantovani A, Allavena P, Sica A and
Balkwill F: Cancer-related inflammation. Nature. 454:436–444. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Juhasz B, Thirunavukkarasu M, Pant R, Zhan
L, Penumathsa SV, Secor ER Jr, Srivastava S, Raychaudhuri U, Menon
VP, Otani H, et al: Bromelain induces cardioprotection against
ischemia-reperfusion injury through Akt/FOXO pathway in rat
myocardium. Am J Physiol Heart Circ Physiol. 294:H1365–H1370. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Ferris RL and Grandis JR: NF-kappaB gene
signatures and p53 mutations in head and neck squamous cell
carcinoma. Clin Cancer Res. 13:5663–5664. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Chen F, Beezhold K and Castranova V: Tumor
promoting or tumor suppressing of NF-kappa B, a matter of cell
context dependency. Int Rev Immunol. 27:183–204. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Hou RC, Chen YS, Huang JR and Jeng KC:
Cross-linked bromelain inhibits lipopolysaccharide-induced cytokine
production involving cellular signaling suppression in rats. J
Agric Food Chem. 54:2193–2198. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Taussig SJ, Szekerczes J and Batkin S:
Inhibition of tumour growth in vitro by bromelain, an extract of
the pineapple plant (Ananas comosus). Planta Med.
51:538–539. 1985. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Kleef R, Delohery TM and Bovbjerg DH:
Selective modulation of cell adhesion molecules on lymphocytes by
bromelain protease 5. Pathobiology. 64:339–346. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Gerard G: Anti-cancer therapy with
bromelain. Agress. 3:261–274. 1972.
|
|
54
|
Nieper HA: A program for the treatment of
cancer. Krebs. 6:124–127. 1974.
|
|
55
|
Philchenkov A: Caspases: potential targets
for regulating cell death. J Cell Mol Med. 8:432–444. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Li Q, Withoff S and Verma IM:
Inflammation-associated cancer: NF-kappaB is the lynchpin. Trends
Immunol. 26:318–325. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Oltersdorf T, Elmore SW, Shoemaker AR,
Armstrong RC, Augeri DJ, Belli BA, Bruncko M, Deckwerth TL, Dinges
J, Hajduk PJ, et al: An inhibitor of Bcl-2 family proteins induces
regression of solid tumours. Nature. 435:677–681. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Netti C, Bandi GL and Pecile A:
Anti-inflammatory action of proteolytic enzymes of animal vegetable
or bacterial origin administered orally compared with that of known
anti-phlogistic compounds. Farmaco Prat. 8:453–466. 1972.
|
|
59
|
Smyth RD, Brennan R and Martin GJ:
Systemic biochemical changes following the oral administration of a
proteolytic enzyme, bromelain. Arch Int Pharmacodyn Ther.
136:230–236. 1962.PubMed/NCBI
|
|
60
|
Garbin F, Harrach T, Eckert K and Maurer
HR: Bromelain proteinase-f9 augments human lymphocyte-mediated
growth-inhibition of various tumor cells in vitro. Int J
Oncol. 5:197–203. 1994.PubMed/NCBI
|
|
61
|
Gläser D and Hilberg T: The influence of
bromelain on platelet count and platelet activity in vitro.
Platelets. 17:37–41. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Kalra N, Bhui K, Roy P, Srivastava S,
George J, Prasad S and Shukla Y: Regulation of p53, nuclear factor
kappaB and cyclooxygenase-2 expression by bromelain through
targeting mitogen-activated protein kinase pathway in mouse skin.
Toxicol Appl Pharmacol. 226:30–37. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Kim JK, Kim Y, Na KM, Surh YJ and Kim TY:
[6]-Gingerol prevents UVB-induced ROS production and COX-2
expression in vitro and in vivo. Free Radic Res. 41:603–614. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Karlsen M, Hovden AO, Vogelsang P, Tysnes
BB and Appel S: Bromelain treatment leads to maturation of
monocyte-derived dendritic cells but cannot replace PGE2 in a
cocktail of IL-1β, IL-6, TNF-α and PGE2. Scand J Immunol.
74:135–143. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Wu SY, Hu W, Zhang B, Liu S, Wang JM and
Wang AM: Bromelain ameliorates the wound microenvironment and
improves the healing of firearm wounds. J Surg Res. 176:503–509.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Wallace JM: Nutritional and botanical
modulation of the inflammatory cascade - eicosanoids,
cyclooxygenases, and lipoxygenases - as an adjunct in cancer
therapy. Integr Cancer Ther. 1:7–37. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Manosroi A, Chankhampan C, Manosroi W and
Manosroi J: Toxicity reduction and MMP-2 stimulation of papain and
bromelain loaded in elastic niosomes. J Biomed Nanotechnol.
8:720–729. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Mynott TL, Guandalini S, Raimondi F and
Fasano A: Bromelain prevents secretion caused by Vibrio
cholerae and Escherichia coli enterotoxins in rabbit
ileum in vitro. Gastroenterology. 113:175–184. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Chandler DS and Mynott TL: Bromelain
protects piglets from diarrhoea caused by oral challenge with K88
positive enterotoxigenic Escherichia coli. Gut. 43:196–202.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Mynott TL, Luke RK and Chandler DS: Oral
administration of protease inhibits enterotoxigenic Escherichia
coli receptor activity in piglet small intestine. Gut.
38:28–32. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Stepek G, Lowe AE, Buttle DJ, Duce IR and
Behnke JM: In vitro and in vivo anthelmintic efficacy of plant
cysteine proteinases against the rodent gastrointestinal nematode,
Trichuris muris. Parasitology. 132:681–689. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Stepek G, Buttle DJ, Duce IR, Lowe A and
Behnke JM: Assessment of the anthelmintic effect of natural plant
cysteine proteinases against the gastrointestinal nematode,
Heligmosomoides polygyrus, in vitro. Parasitology.
130:203–211. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Brakebusch M, Wintergerst U, Petropoulou
T, Notheis G, Husfeld L, Belohradsky BH and Adam D: Bromelain is an
accelerator of phagocytosis, respiratory burst and Killing of
Candida albicans by human granulocytes and monocytes. Eur J
Med Res. 6:193–200. 2001.PubMed/NCBI
|
|
74
|
Massimiliano R, Pietro R, Paolo S, Sara P
and Michele F: Role of bromelain in the treatment of patients with
pityriasis lichenoides chronica. J Dermatolog Treat. 18:219–222.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Tinozzi S and Venegoni A: Effect of
bromelain on serum and tissue levels of amoxicillin. Drugs Exp Clin
Res. 4:39–44. 1978.
|
|
76
|
Luerti M and Vignali ML: Influence of
bromelain on penetration of antibiotics in uterus, salpinx and
ovary. Drugs Exp Clin Res. 4:45–48. 1978.
|
|
77
|
Shahid SK, Turakhia NH, Kundra M, Shanbag
P, Daftary GV and Schiess W: Efficacy and safety of phlogenzym - a
protease formulation, in sepsis in children. J Assoc Physicians
India. 50:527–531. 2002.PubMed/NCBI
|
|
78
|
Neubauer RA: A plant protease for
potentiation of and possible replacement of antibiotics. Exp Med
Surg. 19:143–160. 1961.PubMed/NCBI
|
|
79
|
Ryan RE: A double-blind clinical
evaluation of bromelains in the treatment of acute sinusitis.
Headache. 7:13–17. 1967. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Mori S, Ojima Y, Hirose T, Sasaki T and
Hashimoto Y: The clinical effect of proteolytic enzyme containing
bromelain and trypsin on urinary tract infection evaluated by
double blind method. Acta Obstet Gynaecol Jpn. 19:147–153.
1972.PubMed/NCBI
|
|
81
|
Glade MJ, Kendra D and Kaminski MV Jr:
Improvement in protein utilization in nursing-home patients on tube
feeding supplemented with an enzyme product derived from
Aspergillus niger and bromelain. Nutrition. 17:348–350.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Knill-Jones RP, Pearce H, Batten J and
Williams R: Comparative trial of Nutrizym in chronic pancreatic
insufficiency. BMJ. 4:21–24. 1970. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Balakrishnan V, Hareendran A and Nair CS:
Double-blind cross-over trial of an enzyme preparation in
pancreatic steatorrhoea. J Assoc Physicians India. 29:207–209.
1981.PubMed/NCBI
|
|
84
|
Pellicano R, Strona S, Simondi D, Reggiani
S, Pallavicino F, Sguazzini C, Bonagura AG, Rizzetto M and
Astegiano M: Benefit of dietary integrators for treating functional
dyspepsia: a prospective pilot study. Minerva Gastroenterol Dietol.
55:227–235. 2009.PubMed/NCBI
|
|
85
|
Blonstein JL: Control of swelling in
boxing injuries. Practitioner. 185:781960.PubMed/NCBI
|
|
86
|
Uhlig G and Seifert J: The effect of
proteolytic enzymes (traumanase) on posttraumatic edema. Fortschr
Med. 99:554–556. 1981.(In German). PubMed/NCBI
|
|
87
|
Nieper HA: Effect of bromelain on coronary
heart disease and angina pectoris. Acta Med Empirica. 5:274–278.
1978.
|
|
88
|
Nieper HA: Decrease of the incidence of
coronary heart infarct by Mg- and K-orotate and bromelain. Acta Med
Empirica. 12:614–618. 1977.
|
|
89
|
Seligman B: Oral bromelains as adjuncts in
the treatment of acute thrombophlebitis. Angiology. 20:22–26. 1969.
View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Gutfreund AE, Taussig SJ and Morris AK:
Effect of oral bromelain on blood pressure and heart rate of
hypertensive patients. Hawaii Med J. 37:143–146. 1978.PubMed/NCBI
|
|
91
|
Gailhofer G, Wilders-Truschnig M, Smolle J
and Ludvan M: Asthma caused by bromelain: an occupational allergy.
Clin Allergy. 18:445–450. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Bahde R, Palmes D, Minin E, Stratmann U,
Diller R, Haier J and Spiegel HU: Bromelain ameliorates hepatic
microcirculation after warm ischemia. J Surg Res. 139:88–96. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Bloomer RJ: The role of nutritional
supplements in the prevention and treatment of resistance
exercise-induced skeletal muscle injury. Sports Med. 37:519–532.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Felton GE: Fibrinolytic and antithrombotic
action of bromelain may eliminate thrombosis in heart patients. Med
Hypotheses. 6:1123–1133. 1980. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Lotz-Winter H: On the pharmacology of
bromelain: an update with special regard to animal studies on
dose-dependent effects. Planta Med. 56:249–253. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Shibayama Y: An experimental study into
the cause of acute haemorrhagic gastritis in cirrhosis. J Pathol.
149:307–313. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Kane S and Goldberg MJ: Use of bromelain
for mild ulcerative colitis. Ann Intern Med. 132:6802000.
View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Walker AF, Bundy R, Hicks SM and Middleton
RW: Bromelain reduces mild acute knee pain and improves well-being
in a dose-dependent fashion in an open study of otherwise healthy
adults. Phytomedicine. 9:681–686. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Secor ER, Carson WF, Singh A, Pensa M,
Guernsey LA, Schramm CM and Thrall RS: Oral bromelain attenuates
inflammation in an ovalbumin-induced murine model of asthma. Evid
Based Complement Alternat Med. 5:61–69. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Secor ER Jr, Carson WF IV, Cloutier MM,
Guernsey LA, Schramm CM, Wu CA and Thrall RS: Bromelain exerts
anti-inflammatory effects in an ovalbumin-induced murine model of
allergic airway disease. Cell Immunol. 237:68–75. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Seltzer AP: Adjunctive use of bromelains
in sinusitis: a controlled study. Eye Ear Nose Throat Mon.
46:1281–1288. 1967.PubMed/NCBI
|
|
102
|
Braun JM, Schneider B and Beuth HJ:
Therapeutic use, efficiency and safety of the proteolytic pineapple
enzyme Bromelain-POS in children with acute sinusitis in Germany.
In Vivo. 19:417–421. 2005.PubMed/NCBI
|
|
103
|
Zatuchni GI and Colombi DJ: Bromelains
therapy for the prevention of episiotomy pain. Obstet Gynecol.
29:275–278. 1967.PubMed/NCBI
|
|
104
|
Ahle NW and Hamlet MP: Enzymatic frostbite
eschar debridement by bromelain. Ann Emerg Med. 16:1063–1065. 1987.
View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Rovenská E, Svík K, Stancíková M and
Rovenský J: Enzyme and combination therapy with cyclosporin A in
the rat developing adjuvant arthritis. Int J Tissue React.
21:105–111. 1999.PubMed/NCBI
|
|
106
|
Cohen A and Goldman J: Bromelain's therapy
in rheumatoid arthritis. Pa Med J. 67:27–30. 1964.PubMed/NCBI
|
|
107
|
Grover AK and Samson SE: Benefits of
antioxidant supplements for knee osteoarthritis: rationale and
reality. Nutr J. 15:12016. View Article : Google Scholar : PubMed/NCBI
|
